AcouSort AB (publ) (the “Company”) held an Extraordinary General Meeting (the ”EGM”) on 22 October 2026 in Lund. The EGM resolved, in accordance with the proposal of the Board of Directors, to approve the Board’s resolution on a directed issue of convertible notes to Calyrex Biosystems, Inc. (”Calyrex”).
The EGM resolved, in accordance with the Board of Directors’ proposal, to approve the Boards’ resolution on a directed issue of convertible notes. The right to subscribe for the convertible notes shall, with deviation from the shareholders’ pre-emption rights, accrue to Calyrex.
The resolution entails that the Company raises a convertible loan in a nominal amount of not more than SEK 15,000,000 through the issue of convertible notes to Calyrex, resulting in an increase of the share capital upon full conversion of the convertible notes and accrued interest by not more than SEK 630,263.10, corresponding to a maximum dilution of approximately 22.9 per cent. The convertible notes carry an annual interest rate of 5.0 per cent and mature 30 months after the date of payment, with the right for Calyrex to extend the maturity by an additional 30 months.
For detailed information about the terms for the directed issue and the resolution adopted at the EGM, please see the notice available on the Company’s website, www.acousort.com.